| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2578784 | Thérapie | 2014 | 4 Pages |
Abstract
Although mechanism is unknown, pristinamycine/AVK drug interaction is a reality that needs to be reported in the summary of product characteristics of these drugs and better known by practitioners to act in patients' interest.
Keywords
RCPBNPVINRPharmacovigilanceAVKANSMAMMAFSSAPSvitamin K antagonistAgence française de sécurité sanitaire des produits de santéInteractionDrug interactionrésumé des caractéristiques du produithémorragiesHaemorrhageautorisation de mise sur le marchéInternational Normalized RatioPristinamycinePristinamycinAntivitamine K
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Anne-Laure Guiboux, Anne Dautriche, Fanny Rocher, Mery Bruel, Catherine Sgro, les centres régionaux de pharmacovigilance les centres régionaux de pharmacovigilance,